kappa-lambda flc control set model: 08896577190
"adoc" beograd predstavniŠtvo budva - in vitro dijagnostička medicinska sredstva
victrelis
merck sharp dohme ltd - Боцепревир - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - victrelis je indiciran za liječenje kroničnog hepatitisa c (chc) genotipa 1 infekcije, u kombinaciji s peginterferonom alfa i ribavirinom u odraslih bolesnika s kompenziranom bolešću jetre koji prethodno nisu bili liječeni ili nisu odgovorili na prethodnu terapiju.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
ronapreve 300mg + 300mg rastvor za injekciju/infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - kasirivimab, imdevimab - rastvor za injekciju/infuziju - 300mg + 300mg
ronapreve 120mg/ml + 120mg/ml rastvor za injekciju/infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - kasirivimab, imdevimab - rastvor za injekciju/infuziju - 120mg/ml + 120mg/ml
tremfya
janssen-cilag international nv - guselkumab - psorijaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
labtype
biomedica dijagnostika d.o.o., zagreb - in vitro dijagnostika, identifikacija kodiranih alela s dnk uzorka
microssp typing trays
biomedica dijagnostika d.o.o., zagreb - in vitro dijagnostika, dna pločice za tipizaciju
tremfya 100 mg/1 ml rastvor za injekciju u napunjenom špricu
inpharm co. d.o.o. banja luka - guselkumab - rastvor za injekciju u napunjenom špricu - 100 mg/1 ml - jedan napunjen injekcioni špric sadrži: 100 mg guselkumaba u 1 ml rastvora
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.